

Roche, BMY - Zelboraf (Vemurafenib) approval- Competition to YERVOY starts

<https://marketpublishers.com/r/RCDA5856043EN.html>

Date: August 2011

Pages: 2

Price: US\$ 90.00 (Single User License)

ID: RCDA5856043EN

Abstracts

The USFDA approval of Zelboraf (Vemurafenib) for inoperable metastatic melanoma, well in advance of the PDUFA date is encouraging. USFDA has also approved the cobas BRAF mutation diagnostic test. This will reduce YERVOY uptake directly as ~50% of Metastatic Melanoma patients are B-RAF positive and Zelboraf will be the first line of treatment choice in those patients. We expect Zelboraf to attain peak sales of ~\$1b, and a faster uptake of this personalized medicine. Annual cost of therapy of Zelboraf is \$56,400 vs. \$1,20,000 of YERVOY, which again makes Zelboraf a treatment of choice for B-RAF+ve advanced melanoma patient.

Contents

COMPANIES MENTIONED

Roche, BMY

I would like to order

Product name: Roche, BMY - Zelboraf (Vemurafenib) approval- Competition to YERVOY starts

Product link: <https://marketpublishers.com/r/RCDA5856043EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RCDA5856043EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970